Phase 2b Trial of the PDE10A Inhibitor MK-8189 in People With an Acute Episode of Schizophrenia
These findings suggest that PDE10A inhibition does not have antipsychotic effects at the doses tested.
Authors
- Yuki Mukai (ORCID: https://orcid.org/0000-0002-0000-1199)
- M. A. McEvoy Egan
- Justine Kent
- James Kost
- Jessica Reed
- Theresa Taylor
- Linda Snow-adami
Institutions
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Artistic Realization Technologies (US)
Publication Details
- Journal
- Journal of Clinical Psychopharmacology
- Published
- 2026-02-23
- DOI
- https://doi.org/10.1097/jcp.0000000000002152
- Primary Topic
- Phosphodiesterase function and regulation
- Type
- article
- Field-Weighted Citation Impact
- 0.00